Open-label parallel dose tolerability study of three subcutaneous immunotherapy regimens in house dust mite allergic patients
The current maintenance dose (10,000 AUeq/monthly) of a subcutaneous allergoid for house dust mite (HDM) immunotherapy has previously shown significant clinical efficacy in patients with HDM induced allergic r...